Asset
ILOPERIDONE
Vanda Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04712734 | phase1 | completed | 2021-01-13 | 2022-08-30 | Vanda Pharmaceuticals | A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia |
| NCT05344365 | phase2 | withdrawn | 2022-06-01 | 2023-11-01 | Vanda Pharmaceuticals | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis |
| NCT04969211 | phase1 | completed | 2021-06-30 | 2021-10-13 | Vanda Pharmaceuticals | Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers |
| NCT00254202 | phase3 | completed | 2005-11-18 | 2006-09-26 | Vanda Pharmaceuticals | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia |
| NCT04127058 | phase1 | completed | 2019-10-07 | 2019-11-27 | Vanda Pharmaceuticals | Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 022192 | NDA | VANDA PHARMACEUTICALS INC |
Marketed products (7)
- FANAPT
- FANAPT
- FANAPT
- FANAPT
- FANAPT
- FANAPT
- FANAPT